Selank 5mg

Selank and endogenous peptide signalling

Selank 5mg is a seven-amino-acid synthetic peptide developed from the tuftsin sequence. Its research history connects neurochemical mechanisms with studies of anxiety-related symptoms, offering several ways to investigate the activity of a small regulatory peptide.

The enkephalin research connection

Enkephalins are endogenous signalling peptides whose activity is influenced by enzymatic breakdown. Laboratory work reported that Selank inhibited enkephalin hydrolysis, providing one proposed mechanism for further investigation. Researchers subsequently examined enkephalin-related measurements alongside clinical symptom changes.

Separate receptor experiments studied GABA binding. Together, these findings suggest a research profile involving several interacting signalling systems, rather than a single established explanation of Selank's effects.

Patient studies and the next questions

Small clinical comparisons with medazepam and phenazepam reported improvements in anxiety-related symptoms. These observations are relevant to the continuing investigation of Selank, but broader clinical conclusions depend on larger, well-controlled and independently replicated studies.

Interest in focus and memory overlaps with this research area, although anxiety outcomes are not equivalent to improved cognition in healthy people. The 5mg quantity provides a separate catalogue option for the same named compound, with the same underlying evidence as Selank 10mg.

Also known as / branded as

• Thr-Lys-Pro-Arg-Pro-Gly-Pro
• TKPRPGP